All In Biotech

Drug Trial Radar · NCT06916130

A Study to Compare PK/PD Characteristics and Safety Profiles Between AD-120 and AD-120A

A Randomized, Open-label, Multiple Oral-dose, 2x2 Crossover Clinical Trial to Compare the Safety, Pharmacokinetic, and Pharmacodynamic Characteristics of a AD-120 and AD-120A in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Apr 21, 2025

Primary completion

Sep 1, 2025

Study completion Sep 1, 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Apr 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary endpoint of this study is to evaluate the pharmacokinetic and pharmacodynamic characteristics of AD-120 in healthy subjects.

Conditions

  • Gastroesophageal Reflux Disease (GERD)

Interventions

  • AD-120ADrug

    Administered before the breakfast during 7 days, Oral, Tablet

  • AD-120Drug

    Administered before the breakfast during 7 days, Oral, Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma concentration-time curve over a dosing interval at steady state (AUCτ,ss)Time frame: AUCτ,ss: pre-dose to 24 hours of 1st administration versus pre-dose to 24 hours of repeated administration (7days)
  2. The time of peak concentration after single doseTime frame: Tmax: from pre-dose to 24 hours of 1st administration
  3. Percent decrease from baseline in integrated gastric acidity measured by 24h pH monitoringTime frame: 24 hours before 1st administration to 24 hours after repeated administration (7days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.